We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revance Therapeutics Inc | NASDAQ:RVNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.1301 | -3.93% | 3.1799 | 3.15 | 3.18 | 3.35 | 3.11 | 3.31 | 2,415,980 | 22:13:50 |
|
UNITED STATES
|
||
SECURITIES AND EXCHANGE COMMISSION
|
||
Washington, D.C. 20549
|
||
|
|
|
|
|
|
|
|
|
CURRENT REPORT
|
||
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
Revance Therapeutics, Inc.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
001-36297
|
77-0551645
|
(State or other jurisdiction of incorporation)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Date:
|
August 27, 2019
|
Revance Therapeutics, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Caryn G. McDowell
|
|
|
|
Caryn G. McDowell
|
|
|
|
Senior Vice President, General Counsel & Corporate Secretary
|
1 Year Revance Therapeutics Chart |
1 Month Revance Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions